Illuccix (Gozetotide)

The exact mechanism of action of Gozetotide is not publicly available. It is believed to interact with biological pathways under investigation, but detailed pharmacological targets have not been confirmed.

Dosing of Illuccix is determined by the prescribing healthcare professional based on the clinical context and patient needs. No standard regimen is publicly listed.

Safety of Illuccix in pregnancy or while breastfeeding has not been established. Use only if the potential benefit justifies any potential risk to the mother or infant.

To order Illuccix, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Because the therapeutic class and approved indications for Gozetotide are not publicly defined, direct comparisons with alternative agents cannot be accurately made at this time.

Illuccix should be stored at 2‑8 °C, kept refrigerated, protected from light, and must not be frozen or shaken. Follow all handling instructions provided with the product.

Illuccix is supplied for intravenous administration. It is given by a healthcare professional in a clinical setting according to the prescriber's instructions.

Serious risks have not been identified in publicly available sources. Clinicians should monitor patients closely for any unexpected adverse reactions during and after infusion.

Patients with known hypersensitivity to any component of the formulation should avoid Illuccix. Additionally, due to limited safety data, use in pregnant or breastfeeding individuals is not recommended unless clearly justified.